An analysis of the Dapagliflozin Effect on Cardiovascular Events–Thrombolysis in Myocardial Infarction 58 (DECLARE-TIMI 58) trial with the SGLT2 inhibitor dapagliflozin showed a reduction of new and recurrent AF and atrial flutter events [131]. The gene discussed is SLC5A2; the disease is atrial flutter.